Palifermin and palmar-plantar erythrodysesthesia.
Keijzer
Anita
A
Huijgens
Peter C
PC
van de Loosdrecht
Arjen A
AA
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000009:adverse effects* / Q000627:therapeutic use; D005533:Foot Dermatoses / Q000139:chemically induced*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D008934:Mitogens / Q000009:adverse effects* / Q000627:therapeutic use; D011034:Podophyllotoxin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D008934:Mitogens; D003561:Cytarabine; D051523:Fibroblast Growth Factor 7; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine